Moderna beats Q1 estimates with non-GAAP loss $1.18 per share on revenue of $389M

 

Moderna beats Q1 estimates with non-GAAP loss $1.18 per share on revenue of $389M

• Q1 GAAP loss of $3.40 per share includes a $0.9 billion non-recurring litigation settlement charge.
• Moderna reiterates guidance for up to 10% 2026 revenue growth and expects lower operating expenses.
• The company projects a year-end cash balance totaling $4.5–$5.0 billion in aggregate.

https://finviz.com/quote?t=MRNA&p=d#google_vignette